BrainsWay (NASDAQ:BWAY) Posts Earnings Results, Beats Estimates By $0.03 EPS

BrainsWay (NASDAQ:BWAY) issued its earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03, Zacks reports. BrainsWay had a net margin of 3.88% and a return on equity of 3.56%. The company had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. During the same period last year, the company posted ($0.01) earnings per share. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Stock Performance

Shares of NASDAQ:BWAY traded down $0.60 during trading on Wednesday, hitting $9.10. 149,093 shares of the stock were exchanged, compared to its average volume of 95,611. The company has a market capitalization of $151.79 million, a price-to-earnings ratio of 90.71 and a beta of 1.25. The company’s fifty day simple moving average is $9.11 and its 200-day simple moving average is $7.40. BrainsWay has a 1-year low of $3.80 and a 1-year high of $10.98.

Analyst Ratings Changes

BWAY has been the subject of a number of research reports. Northland Securities boosted their price target on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research report on Thursday, October 3rd. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research note on Monday, October 21st.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.